IN VITRO DIAGNOSTIC QA PLAN SHOULD INCLUDE TREND ANALYSIS
This article was originally published in The Gray Sheet
Executive SummaryIN VITRO DIAGNOSTIC QA PLAN SHOULD INCLUDE TREND ANALYSIS to determine whether there are system failures that can be corrected, FDA's Center for Devices and Radiological Health says in a final draft of the IVD good manufacturing practices guide. Suggesting trend analysis as a way to comply with the requirements of the GMP regulation, FDA says that "product and process accept/reject data results, along with information from complaint files collected through various documented process and control systems, are evaluated by appropriate methods (e.g., trend analysis) to determine if there are recurring problems or process drift which warrant corrective action."
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”